BRAFTOVI encorafenib 50 mg capsule blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

braftovi encorafenib 50 mg capsule blister pack

pierre fabre australia pty ltd - encorafenib, quantity: 50 mg - capsule, hard - excipient ingredients: magnesium stearate; copovidone; iron oxide black; gelatin; iron oxide red; iron oxide yellow; poloxamer; titanium dioxide; crospovidone; colloidal anhydrous silica; microcrystalline cellulose; succinic acid - melanoma,encorafenib, in combination with binimetinib, is indicated for the treatment of adult patients who have unresectable or metastatic melanoma with a braf v600e or v600k mutation, as detected by a validated test.,colorectal cancer,encorafenib, in combination with cetuximab, is indicated for the treatment of adult patients who have metastatic colorectal cancer (mcrc) with a braf v600e mutation as detected by a validated test, and who have received prior systemic therapy.

PHENYTOIN JUNO (phenytoin sodium) 250mg/ 5mL injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

phenytoin juno (phenytoin sodium) 250mg/ 5ml injection ampoule

juno pharmaceuticals pty ltd - phenytoin sodium, quantity: 250 mg - injection, solution - excipient ingredients: sodium hydroxide; water for injections; ethanol; propylene glycol - control of status epilepticus, tonic-clonic (grand mal), psychomotor seizures and the prevention of seizures occuring during or following neurosurgery. phenytoin will prevent or effectively decrease the incidence and severity of convulvsive seizures in a high percentage of cases, with patients exhibiting little tendency to become resistant to its action. besides its effectiveness in controlling seizures, phenytoin frequently improves the mental condition and outlook of epileptic patients. it has also been used in the treatment of certain cardiac arrhythmias, particularly in those patients who do not respond to convential antiarrhythmic agents or to cardioversion. phenytoin serum level determinations may be necessary for optimal dosage adjustments (see dosage and administation).

Kaletra New Zealand - English - Medsafe (Medicines Safety Authority)

kaletra

abbvie limited - lopinavir 200mg; ritonavir 50mg ((pharmacokinetic enhancer)) - film coated tablet - 200mg/50mg. - active: lopinavir 200mg ritonavir 50mg ((pharmacokinetic enhancer)) excipient: colloidal silicon dioxide   hyprolose hypromellose copovidone, k value 28 iron oxide yellow macrogol 3350 macrogol 400 polysorbate 80 purified talc sodium stearyl fumarate sorbitan laurate titanium dioxide - kaletra is indicated for the treatment of hiv-1 infection, in combination with other antiretroviral agents in adults and children aged 2 years and older.

Prezista New Zealand - English - Medsafe (Medicines Safety Authority)

prezista

janssen-cilag (new zealand) ltd - darunavir ethanolate 162.52mg equivalent to darunavir 150 mg - film coated tablet - 150 mg - active: darunavir ethanolate 162.52mg equivalent to darunavir 150 mg excipient: colloidal silicon dioxide crospovidone magnesium stearate opadry white 85f18422 purified water silicified microcrystalline cellulose - adult patients: prezista (with low dose ritonavir as a pharmacokinetic enhancer) is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus-1 (hiv-1) infection in adult patients.

Epanutin Ready Mixed Parenteral 250mg/5ml Solution for Injection or Infusion Ireland - English - HPRA (Health Products Regulatory Authority)

epanutin ready mixed parenteral 250mg/5ml solution for injection or infusion

pfizer healthcare ireland - phenytoin sodium - solution for injection/infusion - 250 mg/5ml - hydantoin derivatives; phenytoin

Triumeq New Zealand - English - Medsafe (Medicines Safety Authority)

triumeq

glaxosmithkline nz limited - abacavir sulfate 702mg equivalent to abacavir 600 mg;  ; dolutegravir sodium 52.6mg equivalent to dolutegravir 50 mg;  ;  ;  ; lamivudine 300mg;   - film coated tablet - 50mg/600mg/300mg - active: abacavir sulfate 702mg equivalent to abacavir 600 mg   dolutegravir sodium 52.6mg equivalent to dolutegravir 50 mg       lamivudine 300mg   excipient: magnesium stearate mannitol microcrystalline cellulose opadry purple 85f90057 povidone sodium starch glycolate - triumeq is indicated for the treatment of human immunodeficiency virus (hiv) infection in adults and adolescents from 12 years of age who are antiretroviral treatment-na?ve or are infected with hiv without documented or clinically suspected resistance to any of the three antiretroviral agents (dolutegravir, abacavir or lamivudine) in triumeq.